Abbvie Inc Financials

ABBV

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Abbvie Inc (ABBV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Revenue

$56.3B

YoY+0.2%

5Y CAGR+14.8%

10Y CAGR+11.9%

Abbvie Inc generated $56.3B in revenue in fiscal year 2024. This represents an increase of 0.2% from the prior year.

EBITDA

$17.5B

YoY-33.7%

5Y CAGR+9.7%

10Y CAGR+9.7%

Abbvie Inc's EBITDA was $17.5B in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 33.7% from the prior year.

Free Cash Flow

$17.8B

YoY-18.9%

5Y CAGR+13.6%

10Y CAGR+11.5%

Abbvie Inc generated $17.8B in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 18.9% from the prior year.

Net Income

$4.3B

YoY-62.9%

5Y CAGR-4.2%

10Y CAGR-2.1%

Abbvie Inc reported $4.3B in net income in fiscal year 2024. This represents a decrease of 62.9% from the prior year.

EPS (Diluted)

$2.39

YoY-62.9%

5Y CAGR-6.2%

10Y CAGR-3.3%

Abbvie Inc earned $2.39 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 62.9% from the prior year.

Cash & Debt

$5.5B

YoY-43.3%

5Y CAGR-9.9%

10Y CAGR-0.7%

Abbvie Inc held $5.5B in cash against $60.3B in long-term debt as of fiscal year 2024.

Dividends Per Share

$6.29

YoY+18.5%

5Y CAGR+19.1%

Abbvie Inc paid $6.29 per share in dividends in fiscal year 2024. This represents an increase of 18.5% from the prior year.

Shares Outstanding

1.77B

YoY-0.2%

5Y CAGR+2.1%

Abbvie Inc had 1.77B shares outstanding in fiscal year 2024. This represents a decrease of 0.2% from the prior year.

Gross Margin

70.0%

YoY+1.0pp

5Y CAGR-5.0pp

10Y CAGR-5.5pp

Abbvie Inc's gross margin was 70.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 1.0 percentage points from the prior year.

Operating Margin

16.2%

YoY-15.7pp

5Y CAGR-17.6pp

10Y CAGR-15.4pp

Abbvie Inc's operating margin was 16.2% in fiscal year 2024, reflecting core business profitability. This is down 15.7 percentage points from the prior year.

Net Margin

7.6%

YoY-13.0pp

5Y CAGR-11.2pp

10Y CAGR-21.1pp

Abbvie Inc's net profit margin was 7.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 13.0 percentage points from the prior year.

Return on Equity

128.7%

YoY+53.9pp

5Y CAGR+24.5pp

Abbvie Inc's ROE was 128.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 53.9 percentage points from the prior year.

R&D Spending

$12.8B

YoY+84.8%

5Y CAGR+20.6%

10Y CAGR+16.5%

Abbvie Inc invested $12.8B in research and development in fiscal year 2024. This represents an increase of 84.8% from the prior year.

Share Buybacks

$1.7B

YoY+82.9%

5Y CAGR+3.9%

Abbvie Inc spent $1.7B on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 82.9% from the prior year.

Capital Expenditures

$974.0M

YoY+23.8%

5Y CAGR+13.0%

10Y CAGR+11.3%

Abbvie Inc invested $974.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 23.8% from the prior year.

ABBV Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$56.3B+0.2%	$56.2B+22.7%	$45.8B+37.7%	$33.3B+1.6%	$32.8B+16.1%	$28.2B
Cost of Revenue	$16.9B-3.1%	$17.4B+13.4%	$15.4B+106.8%	$7.4B-3.6%	$7.7B+9.6%	$7.0B
Gross Profit	$39.4B+1.8%	$38.8B+27.4%	$30.4B+17.8%	$25.8B+3.2%	$25.0B+18.2%	$21.2B
R&D Expenses	$12.8B+84.8%	$6.9B+8.5%	$6.4B-0.4%	$6.4B-38.0%	$10.3B+106.3%	$5.0B
SG&A Expenses	$14.8B+19.5%	$12.3B+9.3%	$11.3B+62.8%	$6.9B-6.2%	$7.4B+17.5%	$6.3B
Operating Income	$9.1B-49.0%	$17.9B+57.7%	$11.4B-12.5%	$13.0B+103.4%	$6.4B-33.1%	$9.5B
Interest Expense	$2.8B+15.9%	$2.4B-1.3%	$2.5B+37.6%	$1.8B+32.3%	$1.3B+17.2%	$1.1B
Income Tax	-$570.0M-139.6%	$1.4B+217.6%	-$1.2B-325.0%	$544.0M+211.0%	-$490.0M-120.3%	$2.4B
Net Income	$4.3B-62.9%	$11.5B+150.0%	$4.6B-41.4%	$7.9B+38.6%	$5.7B+7.1%	$5.3B
EPS (Diluted)	$2.39-62.9%	$6.45+137.1%	$2.72-48.5%	$5.28+44.3%	$3.66+10.9%	$3.30

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q4'23	Q3'24	Q2'24	Q1'24
Revenue	$15.8B+2.3%	$15.4B+15.6%	$13.3B-11.6%	$15.1B+5.6%	$14.3B+2.7%	$13.9B+0.4%	$13.9B+13.4%	$12.2B
Cost of Revenue	$5.3B+22.0%	$4.3B+8.6%	$4.0B-9.0%	$4.4B-22.9%	$5.7B-12.0%	$6.5B+52.9%	$4.2B+6.4%	$4.0B
Gross Profit	$10.5B-5.5%	$11.1B+18.6%	$9.3B-12.7%	$10.7B+24.5%	$8.6B+15.5%	$7.4B-22.7%	$9.6B+16.8%	$8.2B
R&D Expenses	$2.3B+8.8%	$2.1B+3.1%	$2.1B-69.5%	$6.8B+251.5%	$1.9B+11.8%	$1.7B-0.6%	$1.7B-24.4%	$2.3B
SG&A Expenses	$3.6B+9.7%	$3.3B-1.2%	$3.3B-14.6%	$3.9B+20.7%	$3.2B-5.3%	$3.4B+3.2%	$3.3B+7.5%	$3.0B
Operating Income	$1.9B-61.1%	$4.9B+31.1%	$3.7B+350.5%	-$1.5B-146.6%	$3.2B+40.1%	$2.3B-49.5%	$4.5B+63.0%	$2.8B
Interest Expense	$739.0M-0.1%	$740.0M+5.7%	$700.0M-0.3%	$702.0M+24.5%	$564.0M+1.6%	$555.0M+0.5%	$552.0M-0.2%	$553.0M
Income Tax	$526.0M-14.2%	$613.0M+64.8%	$372.0M+116.6%	-$2.2B-678.9%	$388.0M+125.6%	$172.0M-70.5%	$583.0M+149.1%	$234.0M
Net Income	$186.0M-80.2%	$938.0M-27.1%	$1.3B+5945.5%	-$22.0M-102.7%	$822.0M-53.8%	$1.8B-12.2%	$2.0B+746.9%	$239.0M
EPS (Diluted)	$0.10-80.8%	$0.52-27.8%	$0.72+3700.0%	$-0.02-104.3%	$0.46-54.0%	$1.00-12.3%	$1.14+776.9%	$0.13

ABBV Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$135.2B-7.8%	$146.5B-2.7%	$150.6B+69.0%	$89.1B+50.1%	$59.4B-16.2%	$70.8B
Current Assets	$25.6B-8.4%	$27.9B+15.5%	$24.2B-51.2%	$49.5B+192.2%	$16.9B-20.2%	$21.2B
Cash & Equivalents	$5.5B-43.3%	$9.7B+15.4%	$8.4B-78.8%	$39.9B+447.7%	$7.3B-21.6%	$9.3B
Inventory	$4.2B+33.7%	$3.1B-5.5%	$3.3B+82.6%	$1.8B+13.0%	$1.6B0.0%	$1.6B
Accounts Receivable	$10.9B+9.4%	$10.0B+13.1%	$8.8B+62.5%	$5.4B+0.8%	$5.4B+5.8%	$5.1B
Goodwill	$35.0B+8.0%	$32.4B-2.2%	$33.1B+112.3%	$15.6B-0.4%	$15.7B-0.8%	$15.8B
Total Liabilities	$131.8B+0.6%	$131.1B-4.6%	$137.5B+41.3%	$97.3B+43.5%	$67.8B+3.2%	$65.7B
Current Liabilities	$38.7B+10.1%	$35.2B+22.8%	$28.7B+83.9%	$15.6B-9.6%	$17.2B+3.6%	$16.6B
Long-Term Debt	$60.3B-6.0%	$64.2B-17.2%	$77.6B+23.2%	$63.0B+79.9%	$35.0B+13.1%	$31.0B
Total Equity	$3.3B-78.5%	$15.4B+17.9%	$13.1B+260.3%	-$8.2B+3.2%	-$8.4B-265.7%	$5.1B
Retained Earnings	-$7.9B-352.6%	$3.1B+196.4%	$1.1B-77.6%	$4.7B+40.1%	$3.4B-38.3%	$5.5B

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q4'23	Q3'24	Q2'24	Q1'24
Total Assets	$133.9B-2.4%	$137.2B+0.7%	$136.2B+0.7%	$135.2B+0.3%	$134.7B-1.1%	$136.2B+0.6%	$135.4B+0.6%	$134.5B
Current Assets	$28.5B-2.5%	$29.3B+5.7%	$27.7B+8.2%	$25.6B-22.5%	$33.0B-0.7%	$33.2B+15.2%	$28.9B+8.9%	$26.5B
Cash & Equivalents	$5.6B-13.0%	$6.5B+25.0%	$5.2B-6.3%	$5.5B-56.9%	$12.8B-3.6%	$13.3B+51.7%	$8.8B+30.5%	$6.7B
Inventory	$4.9B-0.4%	$5.0B+9.6%	$4.5B+8.3%	$4.2B+2.0%	$4.1B+3.0%	$4.0B-1.8%	$4.1B+5.8%	$3.8B
Accounts Receivable	$12.8B+1.0%	$12.6B+1.3%	$12.5B+14.3%	$10.9B-2.1%	$11.2B-2.3%	$11.4B-0.7%	$11.5B+0.2%	$11.5B
Goodwill	$35.6B0.0%	$35.6B+1.0%	$35.3B+0.9%	$35.0B+8.2%	$32.3B+0.6%	$32.1B-0.4%	$32.2B0.0%	$32.2B
Total Liabilities	$136.5B-0.6%	$137.3B+1.9%	$134.7B+2.2%	$131.8B+6.1%	$124.3B+0.2%	$124.1B+1.3%	$122.5B+1.0%	$121.2B
Current Liabilities	$39.4B-0.9%	$39.8B+9.2%	$36.4B-6.1%	$38.7B+2.4%	$37.8B+8.8%	$34.8B+7.9%	$32.2B+16.9%	$27.6B
Long-Term Debt	$63.0B0.0%	$63.0B-2.4%	$64.5B+6.9%	$60.3B+15.6%	$52.2B-6.2%	$55.6B-0.3%	$55.8B-5.9%	$59.3B
Total Equity	-$2.6B-1814.5%	-$138.0M-109.4%	$1.5B-56.0%	$3.3B-68.0%	$10.4B-14.3%	$12.1B-6.0%	$12.9B-3.0%	$13.3B
Retained Earnings	-$14.2B-23.7%	-$11.5B-20.7%	-$9.5B-20.6%	-$7.9B-690.0%	-$1.0B-207.2%	$933.0M-47.8%	$1.8B-25.2%	$2.4B

ABBV Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$18.8B-17.4%	$22.8B+29.5%	$17.6B+32.0%	$13.3B-0.8%	$13.4B+34.8%	$10.0B
Capital Expenditures	$974.0M+23.8%	$787.0M-1.4%	$798.0M+44.6%	$552.0M-13.5%	$638.0M+20.6%	$529.0M
Free Cash Flow	$17.8B-18.9%	$22.0B+31.0%	$16.8B+31.5%	$12.8B-0.1%	$12.8B+35.6%	$9.4B
Investing Cash Flow	-$20.8B-788.2%	-$2.3B+93.8%	-$37.6B-6401.5%	$596.0M+159.2%	-$1.0B-267.2%	-$274.0M
Financing Cash Flow	-$5.2B+72.6%	-$19.0B-65.5%	-$11.5B-161.5%	$18.7B+230.0%	-$14.4B-161.2%	-$5.5B
Dividends Paid	$11.0B+19.0%	$9.3B+20.0%	$7.7B+21.2%	$6.4B+14.1%	$5.6B+35.9%	$4.1B
Share Buybacks	$1.7B+82.9%	$934.0M-4.5%	$978.0M+55.5%	$629.0M-94.8%	$12.0B+752.1%	$1.4B

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q4'23	Q3'24	Q2'24	Q1'24
Operating Cash Flow	N/A	N/A	$1.6B	N/A	N/A	N/A	N/A	$4.2B
Capital Expenditures	N/A	N/A	$235.0M	N/A	N/A	N/A	N/A	$175.0M
Free Cash Flow	N/A	N/A	$1.4B	N/A	N/A	N/A	N/A	$4.0B
Investing Cash Flow	N/A	N/A	-$735.0M	N/A	N/A	N/A	N/A	-$499.0M
Financing Cash Flow	N/A	N/A	-$1.3B	N/A	N/A	N/A	N/A	-$6.2B
Dividends Paid	N/A	N/A	$2.9B	N/A	N/A	N/A	N/A	$2.7B
Share Buybacks	N/A	N/A	$961.0M	N/A	N/A	N/A	N/A	$2.0B

ABBV Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	70.0%+1.0pp	69.0%+2.5pp	66.4%-11.2pp	77.6%+1.2pp	76.4%+1.4pp	75.0%
Operating Margin	16.2%-15.7pp	31.9%+7.1pp	24.8%-14.2pp	39.0%+19.5pp	19.5%-14.3pp	33.8%
Net Margin	7.6%-13.0pp	20.5%+10.5pp	10.1%-13.6pp	23.7%+6.3pp	17.4%-1.5pp	18.8%
Return on Equity	128.7%+53.9pp	74.8%+39.5pp	35.2%	N/A	N/A	104.2%
Return on Assets	3.2%-4.7pp	7.9%+4.8pp	3.1%-5.8pp	8.8%-0.7pp	9.6%+2.1pp	7.5%
Current Ratio	0.66-0.1	0.79-0.0	0.84-2.3	3.18+2.2	0.98-0.3	1.28
Debt-to-Equity	18.15+14.0	4.16-1.8	5.92+13.6	-7.71-3.6	-4.14-10.2	6.07
FCF Margin	31.6%-7.5pp	39.1%+2.5pp	36.7%-1.7pp	38.4%-0.7pp	39.1%+5.6pp	33.4%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q4'23	Q3'24	Q2'24	Q1'24
Gross Margin	66.4%-5.4pp	71.8%+1.8pp	70.0%-0.9pp	70.9%+10.8pp	60.1%+6.7pp	53.4%-16.0pp	69.4%+2.0pp	67.4%
Operating Margin	12.1%-19.7pp	31.7%+3.8pp	28.0%+37.9pp	-9.9%-32.2pp	22.3%+6.0pp	16.4%-16.2pp	32.6%+9.9pp	22.6%
Net Margin	1.2%-4.9pp	6.1%-3.6pp	9.6%+9.8pp	-0.1%-5.9pp	5.8%-7.0pp	12.8%-1.8pp	14.6%+12.6pp	2.0%
Return on Equity	25.7%+5.6pp	20.1%-67.9pp	88.0%	N/A	7.9%-6.8pp	14.7%-1.0pp	15.7%+13.9pp	1.8%
Return on Assets	0.1%-0.5pp	0.7%-0.3pp	0.9%+1.0pp	-0.0%-0.6pp	0.6%-0.7pp	1.3%-0.2pp	1.5%+1.3pp	0.2%
Current Ratio	0.72-0.0	0.74-0.0	0.76+0.1	0.66-0.2	0.87-0.1	0.96+0.1	0.89-0.1	0.96
Debt-to-Equity	-23.83+432.4	-456.22-500.4	44.14+26.0	18.15+13.1	5.02+0.4	4.59+0.3	4.33-0.1	4.46
FCF Margin	N/A	N/A	10.5%	N/A	N/A	N/A	N/A	32.9%

Note: The current ratio is below 1.0 (0.66), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Financial Health Signals

Financial Profile 53/100

Profitability

Growth

Leverage

Liquidity

Cash Flow

100

Returns

100

Based on FY2024 annual data. Scores normalized against common benchmarks.

Altman Z-Score Grey Zone

2.27

Bankruptcy risk indicator. Above 2.99 = safe, below 1.81 = distress.

Piotroski F-Score Neutral

6/9

Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.

Earnings Quality Cash-Backed

4.40x

Operating cash flow vs net income. Above 1.0x = cash-backed earnings.

Interest Coverage Adequate

3.3x

Operating income vs interest expense. Above 5x = safe, below 2x = risky.

Similar Companies

Johnson & Johnson JNJ

$589.2B

$317.1B

$307.6B

$929.3B

$217.6B

Frequently Asked Questions

What is Abbvie Inc's annual revenue?

Abbvie Inc (ABBV) reported $56.3B in total revenue for fiscal year 2024. This represents a 0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Abbvie Inc's revenue growing?

Abbvie Inc (ABBV) revenue grew by 0.2% year-over-year, from $56.2B to $56.3B in fiscal year 2024.

Is Abbvie Inc profitable?

Yes, Abbvie Inc (ABBV) reported a net income of $4.3B in fiscal year 2024, with a net profit margin of 7.6%.

What is Abbvie Inc's earnings per share (EPS)?

Abbvie Inc (ABBV) reported diluted earnings per share of $2.39 for fiscal year 2024. This represents a -62.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Abbvie Inc's EBITDA?

Abbvie Inc (ABBV) had EBITDA of $17.5B in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Abbvie Inc have?

As of fiscal year 2024, Abbvie Inc (ABBV) had $5.5B in cash and equivalents against $60.3B in long-term debt.

What is Abbvie Inc's gross margin?

Abbvie Inc (ABBV) had a gross margin of 70.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Abbvie Inc's operating margin?

Abbvie Inc (ABBV) had an operating margin of 16.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Abbvie Inc's net profit margin?

Abbvie Inc (ABBV) had a net profit margin of 7.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Does Abbvie Inc pay dividends?

Yes, Abbvie Inc (ABBV) paid $6.29 per share in dividends during fiscal year 2024.

What is Abbvie Inc's return on equity (ROE)?

Abbvie Inc (ABBV) has a return on equity of 128.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Abbvie Inc's free cash flow?

Abbvie Inc (ABBV) generated $17.8B in free cash flow during fiscal year 2024. This represents a -18.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Abbvie Inc's operating cash flow?

Abbvie Inc (ABBV) generated $18.8B in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Abbvie Inc's total assets?

Abbvie Inc (ABBV) had $135.2B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Abbvie Inc's capital expenditures?

Abbvie Inc (ABBV) invested $974.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Abbvie Inc spend on research and development?

Abbvie Inc (ABBV) invested $12.8B in research and development during fiscal year 2024.

Does Abbvie Inc buy back shares?

Yes, Abbvie Inc (ABBV) spent $1.7B on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Abbvie Inc have outstanding?

Abbvie Inc (ABBV) had 1.77B shares outstanding as of fiscal year 2024.

What is Abbvie Inc's current ratio?

Abbvie Inc (ABBV) had a current ratio of 0.66 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Abbvie Inc's debt-to-equity ratio?

Abbvie Inc (ABBV) had a debt-to-equity ratio of 18.15 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Abbvie Inc's return on assets (ROA)?

Abbvie Inc (ABBV) had a return on assets of 3.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Abbvie Inc's Altman Z-Score?

Abbvie Inc (ABBV) has an Altman Z-Score of 2.27, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress.

What is Abbvie Inc's Piotroski F-Score?

Abbvie Inc (ABBV) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Are Abbvie Inc's earnings high quality?

Abbvie Inc (ABBV) has an earnings quality ratio of 4.40x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

Can Abbvie Inc cover its interest payments?

Abbvie Inc (ABBV) has an interest coverage ratio of 3.3x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline.

How financially healthy is Abbvie Inc?

Abbvie Inc (ABBV) scores 53 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.